Active Biotech AB Interim report January – September 2012

Nov 9, 2012 08:30 (CET)
· Laquinimod – Teva to initiate a new Phase III study in the US at year-end
                   – milestone payment of USD 5 M received following a submitted application for regulatory approval in Europe
                   – Crohn’s Phase II data presented at the UEGW conference

· TASQ        – biomarker data presented at the ESMO conference 
                   – Ipsen to initiate two new clinical Phase II studies: maintenance therapy for prostate cancer and a study of other types of cancer
 
· ANYARA   – Phase III study results to be presented Q1 2013

· 57-57        – clinical trial of systemic sclerosis/scleroderma is in progress

· ISI            – project proceeding as planned

· Net sales:  SEK 136.4 M (231.3)

· Operating loss: SEK 168.7 M (loss 6.2)

· Loss after tax: SEK 175.1 M (loss: 1.3)

· Loss per share for the period: SEK 2.54 (loss: 0.02) 

 
For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95    

Hans Kolam 
CFO 
Tel: +46 (0)46 19 20 44  

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00 
Fax: +46 (0)46 19 11 00

This report is also available at www.activebiotech.com  

Active Biotech AB Interim report January – September 2012

—
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE
HUG#1656396